mergers & acquisitions
Biosynex to Acquire Chembio Diagnostics for $17.2M
Biosynex will buy all of Chembio's shares at $.45 per share in an all-cash deal that merges two developers and makers of point-of-care diagnostic tests.
Sherlock Biosciences to Acquire Sense Biodetection
The firms intend to combine Sherlock's CRISPR technology and Sense's rapid molecular amplification chemistries, accelerating Sherlock's go-to-market strategy.
Among potential growth opportunities, the firm's new CEO noted hospital lab M&A and STD and cancer testing.
Both the number of mergers and acquisitions and the size of deals decreased in 2022 compared to the highs of 2021 and 2020.
Top 10 Articles on 360Dx in 2022
In 2022 readers were most interested in a story about what happened to Cepheid's GeneXpert Omni, a point-of-care platform once touted by the company.